Australian biotech market watch 02/10/09
Friday, 02 October, 2009
The All Ordinaries has followed the Dow Jones and other international indices by dropping nearly 2% in today's trading on the back of fears of continued economic strife in the United States. The health index managed to keep the slide to a minimum, shedding only 0.7%.
At the forefront of the losses was Biota Holdings (ASX:BTA), which receives royalties for the anti-viral drug, Relenza, which dropped 2.8% to $2.77.
Ramsay Health Care (ASX:RHC) also lost 2% of its value, down to $10.86, bringing it back to its Monday start after peaking at $11.10 mid-week.
Medical implant company, Cochlear (ASX:COH) saw a $1.15 dip to $66.42, and CSL (ASX:CSL) slipped 22c to $33.22.
It wasn't all bad news though. Blackmores (ASX:BKL) nudged upwards half a per cent to $20.23, after having a shaky start this morning.
Photoprotective drug company, Clinuvel (ASX:CUV) also saw a late jump of over 10% to $0.38, putting its stock at a four month high.
Breast augmentation procedure uses 3D-printed scaffolds
3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...
Victoria detects H5N1 avian influenza strain
It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
